NJ A3621

Prohibits manufacturers and wholesale distributors from engaging in "price gouging" on essential off-patent or generic drugs, defined as excessive price increases not justified by production costs or access expansion, where consumers have no affordable alternatives

Applies to drugs on the WHO Model List of Essential Medicines or designated essential by the Commissioner of Health, with expired exclusive marketing rights, manufactured by three or fewer companies, and sold in New Jersey

Triggers investigation when price increases 50% or more within one year and the drug costs more than $80 for a 30-day supply or full course of treatment

Requires manufacturers to submit detailed cost statements to the Attorney General within 45 days upon request, including production costs, materials increases, and expenditures to expand access

Authorizes courts to issue injunctions, order consumer refunds, require manufacturers to sell at pre-violation prices for up to one year, and impose civil penalties up to $10,000 per sale constituting price gouging